Expression profile of PBMCs following decitabine treatment
Ontology highlight
ABSTRACT: The epigenetic regulation, for example, DNA methylation, controls the development and differentiation of both tumor cells and immunocytes. Treatment with DNA demethylating agent (such as decitabine) has shown a dramatic clinical benefit in hematological malignancies and solid tumors. However, the influence of epigenetic therapy on host immune system remains unclear. To investigate the effects of low-dose decitabine therapy on T cells, We collected whole blood samples from two solid tumor patients pre and post low-dose decitabine therapy, and detected the expression profiles of PBMCs.
ORGANISM(S): Homo sapiens
SUBMITTER: Jing Nie
PROVIDER: E-GEOD-72686 | biostudies-arrayexpress |
REPOSITORIES: biostudies-arrayexpress
ACCESS DATA